Revefenacin clinical trials
Also written TD-4208 and Yupelri.
How each study uses revefenacin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the revefenacin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 9 Nov 2018 · YUPELRI · NDA 210598 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
21 studies that test it; most in 2015 (6)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 6 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 4
Mylan Inc. (13) · University of Tennessee Graduate School of Medicine (3) · Mylan Pharma UK Ltd. (2) · University of California, Los Angeles (1) · Theravance Biopharma (1) · GlaxoSmithKline (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Cholinergic Antagonists source
- One of Antimuscarinics source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test revefenacin.
- Dec 2026Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting BronchodilatorsPhase 4 · University of Tennessee Graduate School of Medicine
Studies
Open first, then newest update. How each study uses revefenacin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 21
- Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)Not yet recruitingPhase 4University of Tennessee Graduate School of MedicineNCT07721922Written as RevefenacinHow we know
- Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting BronchodilatorsRecruitingPhase 4University of Tennessee Graduate School of MedicineNCT07133880Written as Revefenacin 175 µg, Formoterol 20 µgHow we know
- Revefenacin in Acute Respiratory Insufficiency in COPDCompletedPhase 2University of California, Los AngelesNCT04315558Written as Revefenacin Inhalation Solution [Yupelri]How we know
- Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPDCompletedPhase 4University of Tennessee Graduate School of MedicineNCT04655170Written as Revefenacin (YUPELRI) & Formoterol (Perforomist)How we know
- Phase 4 COPD and Suboptimal Inspiratory Flow RateCompletedPhase 4Theravance BiopharmaNCT05165485Written as RevefenacinHow we know
- Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)CompletedPhase 3Mylan Pharma UK Ltd.NCT05046795Written as Revefenacin 175 mcg in 3 ML Inhalation SolutionHow we know
- Fasting Bioavailability Study of Mylan's Revefenacin Inhalation SolutionCompletedPhase 1Mylan Pharma UK Ltd.NCT05207111Written as Revefenacin Inhalation SolutionHow we know
- Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic ImpairmentCompletedPhase 1Mylan Inc.NCT02581592Written as TD-4208How we know
- Pharmacokinetics of TD-4208 in Patients With Severe Renal ImpairmentCompletedPhase 1Mylan Inc.NCT02578082Written as TD-4208How we know
- Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3Mylan Inc.NCT02459080Written as TD-4208How we know
- A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2Mylan Inc.NCT02040792Written as TD-4208How we know
- 7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedPhase 2Mylan Inc.NCT01704404Written as TD-4208How we know
- A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2Mylan Inc.NCT02109172Written as TD-4208How we know
- A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3Mylan Inc.NCT02518139Written as TD-4208How we know
- Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3Mylan Inc.NCT02512510Written as TD-4208How we know
- A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPDCompletedPhase 3Mylan Inc.NCT03573817Written as RevefenacinHow we know
- Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2Mylan Inc.NCT03064113Written as TD-4208 700 μgHow we know
- TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male SubjectsCompletedPhase 1Mylan Inc.NCT02772159Written as TD-4208How we know
- Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPDCompletedPhase 3Mylan Inc.NCT03095456Written as RevefenacinHow we know
- Thorough QT (TQT) Study of TD-4208 in Healthy SubjectsCompletedPhase 1Mylan Inc.NCT02820311Written as TD-4208 175 mcgHow we know
Codes
What other systems call revefenacin · ClinicalTrials.gg INT006351
- MeSH (NLM) C583570revefenacinOne source NLM
- UNII (FDA) G2AE2VE07OREVEFENACINConfirmed FDA, NLM, Wikidata
- RxNorm 2102775One source FDA
- Wikidata Q27278649revefenacinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152200RevefenacinOne source FDA
- DrugBank DB11855One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C583570 | revefenacin | One source NLM |
| UNII (FDA) | G2AE2VE07O | REVEFENACIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2102775 | — | One source FDA |
| Wikidata | Q27278649 | revefenacin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152200 | Revefenacin | One source FDA |
| DrugBank | DB11855 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.